EMPLOYMENT AGREEMENTEmployment Agreement • February 21st, 2024 • Theratechnologies Inc. • Pharmaceutical preparations
WHEREAS Thera is a Canadian biopharmaceutical company engaged in the research, development and commercialization of therapeutic products;
AMENDMENT TO MANUFACTURE AND SUPPLY AGREEMENTManufacture and Supply Agreement • February 21st, 2024 • Theratechnologies Inc. • Pharmaceutical preparations
WHEREAS Purchaser and Supplier signed a Manufacture and Supply Agreement dated as of December 23, 2009, as amended from time to time (the “MSA”);
AMENDMENT #2 TO SHARE PURCHASE AGREEMENT AMONG: TRANSFERT PLUS, L.P. AND ALIGO INNOVATION, L.P. AND BORHANE ANNABI AND RICHARD BÉLIVEAU AND CYNDIA CHARFI AND JEAN-CHRISTOPHE CURRIE AND ALAIN LAROCQUE AND MICHEL DEMEULE AND SOPHIE KOZELKO AND...Share Purchase Agreement • February 21st, 2024 • Theratechnologies Inc. • Pharmaceutical preparations • Quebec
WHEREAS the Purchaser and the Vendors have entered into a share purschase agreement dated February 25, 2019 (the “Share Purchase Agreement”), as amended on August 12, 2019 (the “First Amendment”) (the Share Purchase Agreement and the First Amendment, collectively the “Share Purchase Agreement”), pursuant to which Purchaser purchased from the Vendors all of the issued and outstanding common shares of Katana Biopharma Inc.;
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • February 21st, 2024 • Theratechnologies Inc. • Pharmaceutical preparations
WHEREAS the Employee is employed by Thera since May 7, 2007 following the execution of an employment contract dated April 13, 2007, as amended May 23, 2012 and July 17, 2012 (the “employment contract”); and
EMPLOYMENT CONTRACTEmployment Contract • February 21st, 2024 • Theratechnologies Inc. • Pharmaceutical preparations • Quebec
EMPLOYMENT CONTRACTEmployment Contract • February 21st, 2024 • Theratechnologies Inc. • Pharmaceutical preparations
WHEREAS Thera wishes to hire the Employee to act as Senior Vice President and Chief Financial Officer in accordance with the terms and conditions contained herein; and
PERSONAL AND CONFIDENTIAL Montreal, July 31, 2023 John Leasure RE: Amendment to your Employment Agreement Dear John:Personal And • February 21st, 2024 • Theratechnologies Inc. • Pharmaceutical preparations
Further the decision of the board of directors of Theratechnologies Inc. (“Thera”) to harmonize the terms and conditions of all of the employment agreements of the executive officers related to a termination without a serious reason and a termination in the event of a change of control of Thera or other material transactions involving Thera, we hereby offer you to amend Sections 16.3 and 16.4 of your employment agreement dated January 6, 2023 (with an effective date of April 11, 2022) (the “Agreement”) as follows:
FIRST AMENDMENT TO THE AMENDED & RESTATED LICENSE AGREEMENTLicense Agreement • February 21st, 2024 • Theratechnologies Inc. • Pharmaceutical preparations
This FIRST AMENDMENT to the AMENDED & RESTATED LICENSE AGREEMENT (“First Amendment”) is made as of the 15th day of April, 2020 (“First Amendment Effective Date”) between Theratechnologies, Inc., a Québec company, having a principal place of business at 2015 Peel Street, 11th Floor, Montréal, Québec H3A 1T8 (“Company”) and The General Hospital Corporation, d/b/a Massachusetts General Hospital, a not-for-profit Massachusetts corporation, having a principal place of business at 55 Fruit St., Boston, MA 02114. (“Institution”), each referred to herein individually as a “Party” or collectively as the “Parties”.
MANUFACTURING AND SUPPLY AGREEMENTManufacturing and Supply Agreement • February 21st, 2024 • Theratechnologies Inc. • Pharmaceutical preparations
WHEREAS Thera is a biopharmaceutical company which specializes in the research and the development of therapeutic peptides;
AMENDMENT #3 to Amended and Restated Distribution and Marketing Agreement (the “Agreement”) TERM SHEETDistribution and Marketing Agreement • February 21st, 2024 • Theratechnologies Inc. • Pharmaceutical preparations
AMENDMENT TO MANUFACTURE AND SUPPLY AGREEMENTManufacture and Supply Agreement • February 21st, 2024 • Theratechnologies Inc. • Pharmaceutical preparations
WHEREAS Purchaser and Supplier signed a Manufacture and Supply Agreement dated as of December 23, 2009, as amended from time to time (the “MSA”);
AMENDMENT #2Distribution and Marketing Agreement • February 21st, 2024 • Theratechnologies Inc. • Pharmaceutical preparations
This AMENDMENT #2 TO AMENDED AND RESTATED DISTRIBUTION AND MARKETING AGREEMENT (the “Amendment”), effective as of November 5, 2019 (the “Amendment Effective Date”), is made by and between TAIMED BIOLOGICS INC., a Taiwan corporation with the registered company address at 3F, No. 607, Ruiguang Road, Neihu District, Taipei City 11492, Taiwan, R.O.C. (“TaiMed”), and THERATECHNOLOGIES INC., a Canadian corporation organized under the laws of the Province of Quebec having its head office and principal place of business located at 2015 Peel Street, 5th floor, in the City of Montreal, Province of Quebec, Canada H3A 1T8 (“Theratechnologies”).
THIRD AMENDMENT TO AMENDED AND RESTATED MASTER SERVICES AGREEMENTMaster Services Agreement • February 21st, 2024 • Theratechnologies Inc. • Pharmaceutical preparations
This Third Amendment to Master Services Agreement (this “Amendment”) dated December 1, 2021 (“Amendment Effective Date”) by and between Syneos Health Commercial Services, LLC (f/k/a inVentiv Commercial Services, LLC) a Syneos Health® group company (“Syneos Health”) and Theratechnologies, Inc. (“Client”). Client and Syneos Health may each be referred to herein as a “Party” and collectively, the “Parties”.
THIS EMPLOYMENT AGREEMENT is made as of the 6th day of January 2023 with an effective date as of April 11, 2022 (the “Effective Date”)Employment Agreement • February 21st, 2024 • Theratechnologies Inc. • Pharmaceutical preparations • Quebec
FIRST AMENDMENT TO THE AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENTExclusive License • February 21st, 2024 • Theratechnologies Inc. • Pharmaceutical preparations • Quebec
NOW THEREFORE IN CONSIDERATION of the above recitals and the mutual benefits to be derived hereafter, the Parties agrees as follows:
CONSULTING AGREEMENTConsulting Agreement • February 21st, 2024 • Theratechnologies Inc. • Pharmaceutical preparations
WHEREAS Thera is a Canadian biopharmaceutical company involved in research and development, manufacture and commercialization of pharmaceutical products;
